Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain

Ahmed Abdelhak; Jens Kuhle; Ari J Green

doi:10.1001/jamaneurol.2023.0394

Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain

JAMA Neurol. 2023 Jun 1;80(6):542-543. doi: 10.1001/jamaneurol.2023.0394.

Authors

Ahmed Abdelhak¹, Jens Kuhle^{2

3}, Ari J Green¹

Affiliations

¹ Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco.
² Department of Neurology, University of Basel, Basel, Switzerland.
³ Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, Basel, Switzerland.

PMID: 37010852
DOI: 10.1001/jamaneurol.2023.0394

No abstract available

Plain language summary

This Viewpoint describes the benefits and limitations of using neurofilament light chain (NfL) as a marker of real-time disease activity and treatment response in multiple sclerosis.

MeSH terms

Biomarkers
Humans
Intermediate Filaments*
Multiple Sclerosis*
Neurofilament Proteins

Substances

Biomarkers
Neurofilament Proteins